Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CHyMERA

Financiado

Cerrado

Monitoring cancer heterogeneity based on the dynamic assessment of the Warburg e...

Monitoring cancer heterogeneity based on the dynamic assessment of the Warburg effect under metabolic perturbation Cancer heterogeneity is reflected in the multitude of phenotypes found in the clinic, with different proliferation statuses and metastatic potentials. These features cannot be assessed with the molecular imaging methods commonly a... ver más

01/05/2021

FUNDACAO CHAMPALIM...

160K€

Presupuesto del proyecto: 160K€

Líder del proyecto

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-05-01

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACAO CHAMPALIMAUD

159.82K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ImageLink Multiparametric tumor imaging and beyond Towards understand... 2M€ Cerrado

Metabonomics in NETs Evolving landscape of neuroendocrine tumor disease Predicti... 209K€ Cerrado

MICRONEX Microbioreactor platforms as in vivo like systems to probe t... 1M€ Cerrado

Tx-phylogeography High throughput phylogeography of tumors: how the tissue en... 2M€ Cerrado

MR O MICS Unravelling Tumour Biology In Ovarian Cancer With Precision... 1M€ Cerrado

CANCERINNOVATION Using novel methodologies to target and image cancer invasio... 2M€ Cerrado

Duración del proyecto: 25 meses Fecha Inicio: 2019-03-25
Fecha Fin: 2021-05-01

Líder del proyecto

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 160K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer heterogeneity is reflected in the multitude of phenotypes found in the clinic, with different proliferation statuses and metastatic potentials. These features cannot be assessed with the molecular imaging methods commonly available for diagnosis and monitoring. The main goal of this proposal is to develop a molecular imaging methodology based on endogenous contrast – CHyMERA – and demonstrate its feasibility to image hotspot areas of active proliferation and metastatic potential. The approach is based on the concept of cancer metabolic plasticity, does not require contrast agents or radioactive tracers, and should ultimately provide more specificity to cancer diagnosis and treatment planning than other imaging methods currently available. We propose to use animal models of human cancer, a glucose-enhanced imaging method, and an objective analysis of regional metabolic responses to controlled, reversible changes in the tumour microenvironment (perturbations), such as transient hypoxia. Specifically, we will (i) develop and validate CHyMERA at ultra-high magnetic fields, to monitor the metabolic kinetics of glucose and lactate in the tumour microenvironment. This methodology will be (ii) applied in vivo to two immunocompetent mouse model of GBM (allograft and genetically engineered models), to image vascular permeability/perfusion and hotspots of glioma proliferation. Finally, we will (iii) carry out a pilot study with two isogenic mouse models breast of cancer, metastatic and non-metastatic, to generate hotspots maps of proliferation and metastatic potential. All in vivo results will be validated post-mortem by immunohistochemistry. If successful, this methodology has a strong potential for clinical translational, which the host institution is ideally suited to test.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores